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Abstract
Purpose: Previous studies have suggested that postmenopausal women with breast cancer who present with wild-type
CYP2D6 may actually have similar or superior recurrence-free survival outcomes when given tamoxifen in place of
aromatase inhibitors (AIs). The present study established a CYP2D6 multiple-genotype-based model to determine the
optimal endocrine therapy for patients harboring wild-type CYP2D6.
Methods: We created a Markov model to determine whether tamoxifen or AIs maximized 5-year disease-free survival (DFS)
for extensive metabolizer (EM) patients using annual hazard ratio (HR) data from the BIG 1-98 trial. We then replicated the
model by evaluating 9-year event-free survival (EFS) using HR data from the ATAC trial. In addition, we employed two-way
sensitivity analyses to explore the impact of HR of decreased-metabolizer (DM) and its frequency on survival by studying a
range of estimates.
Results: The 5-year DFS of tamoxifen-treated EM patients was 83.3%, which is similar to that of genotypically unselected
patients who received an AI (83.7%). In the validation study, we further demonstrated that the 9-year EFS of tamoxifen-
treated EM patients was 81.4%, which is higher than that of genotypically unselected patients receiving tamoxifen (78.4%)
and similar to that of patients receiving an AI (83.2%). Two-way sensitivity analyses demonstrated the robustness of the
results.
Conclusions: Our modeling analyses indicate that, among EM patients, the DFS/EFS outcome of patients receiving
tamoxifen is similar to that of patients receiving an AI. Further prospective clinical trials are needed to evaluate the value of
the CYP2D6 genotype in the selection of endocrine therapy.
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Introduction
Adjuvant tamoxifen is a fundamental systemic therapy for
patients with hormone receptor-positive breast cancer [1]. Two
minor but extremely active metabolites of tamoxifen, 4-hydro-
xytamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen),
have been indicated to be predominantly catalyzed by cytochrome
P450 2D6 (CYP2D6) [2]. The plasma concentrations of endoxifen
could be affected by the genotypes coding for the CYP2D6 enzyme
[3].Therefore,the clinical efficacy of tamoxifenmayvary according
to CYP2D6 genotypes. The CYP2D6 gene is highly polymorphic,
and its phenotypes are usually categorized into four groups: poor
metabolizer (PM), intermediate metabolizer (IM), extensive metab-
olizer (EM), and ultra-rapid metabolizer (UM) [4–6].
In recent years, the role of tamoxifen in postmenopausal breast
cancer patients has been challenged by aromatase inhibitors (AIs)
[7,8], which have been considered to be an optimal adjuvant
endocrine treatment for postmenopausal women with hormone
receptor-positive breast cancer [9–11]. However, there is concern
that the up-front use of AIs does not result in an improvement in
the overall survival compared with tamoxifen. Moreover, AIs do
not always represent the ideal therapy for postmenopausal women
because of the more common and severe musculoskeletal
complaints and the higher risk of osteoporosis [12,13]. In addition,
AIs are expensive. Although some investigators [14,15] have
asserted that AIs are more cost-effective in an adjuvant setting, the
cost of AIs varies vastly among countries (e.g., in China,
anastrozole CNY1400/month vs. tamoxifen CNY30/month; in
Locker’s report [14]: anastrozole $6.56/day vs. tamoxifen $1.33/
day). Considering the absolute 5-year disease-free survival (DFS)
difference between tamoxifen and AIs is 2–4% [7,8], the ability to
select the patients who are likely to have a better response to AIs
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women homozygous for the CYP2D6*4 allele (the most common
PM allele in Caucasians [16]) had significantly lower plasma
endoxifen concentrations [3] and worse clinical outcomes than
women heterozygous or homozygous for the common alleles when
given tamoxifen [17–21]; however, not all epidemiologic evidence
supports this observation [22–24].
Recently, Punglia et al. [25] established a model using data
from Goetz’s study [17] to estimate whether women with wild-type
CYP2D6 have superior DFS outcomes if they receive tamoxifen
rather than an AI. By applying the model, Punglia et al. proposed
that women with wild-type CYP2D6 actually had a similar or lower
rate of relapse when treated with tamoxifen compared with an AI.
Given that approximately 70% of women harbor wild-type
CYP2D6, the role of CYP2D6 genotype testing may be critical
for selecting the optimal adjuvant endocrine treatment for
postmenopausal patients [25].
Before the real-world application of the model developed by
Punglia et al. [25], some questions should be resolved. First, the
model is based on a relatively small sample size (n=223) from a
prospective cohort of the US North Central Cancer Treatment
Group (NCCTG) 89-30-52 trial. Therefore, the representation of
thosedata is limited and questionable. Of note, a recent JAMA article
[26] reported updated results by combining data from a retrospective
German breast cancer cohort with the original data from the
NCCTG 89-30-52 trial cohort, resulting in a larger sample size
(n=1,325) and a median follow-up time of 6.3 years. It is necessary to
reevaluate the old model using new and more convincing data. In
addition, the model developed by Punglia et al. solely focuses on the
CYP2D6*4 allele. Although *4 is the most frequent PM allele in
Caucasians, other PM/IM alleles, including *3, *5, *6, *10, and *41,
are also relatively common [6,16]. Thus, a new model based on
multiple genotypes should be proposed.
The aim of the present study was to establish a model using
multiple-genotype-based data from a large sample size study to
better determine whether treatment with an AI or tamoxifen is the
optimal adjuvant endocrine therapeutic choice for postmenopaus-
al patients harboring wild-type CYP2D6 enzymatic activity. The
survival data for modeling was obtained from the Breast
International Group (BIG) 1-98 trial [8]. In addition, our results
were further validated using survival data in another large trial
Arimidex, Tamoxifen, Alone or in Combination (ATAC) [7].
Materials and Methods
Data collection and assumptions
Annual hazard rates. Model estimates for relapse
probabilities by initial treatment (AI or tamoxifen) were derived
from the annual hazard rates in BIG 1-98 and ATAC trials
(Table 1). Annual hazard rates in the BIG 1-98 trial was retrieved
as previously described [25]. Annual hazard rates in the ATAC
trial were obtained by measuring the annual hazard curves for
time to recurrence in the article using the Measure Tool of Adobe
Acrobat 7.0 Professional (Adobe Systems Inc., San Jose,
California). A hazard rate at the middle of a given year was
measured to represent the annual hazard rate. We assumed that
the relapse probabilities during a given year were constant. We
also assumed that neither the hazard rate for relapse on AIs nor
the tumor characteristics were affected by metabolizer status and
CYP2D6 genotype.
Data sources for CYP2D6 multiple-genotype-based
modeling analyses. To construct a multiple-genotype-based
model, we collected the data from the study by Schroth et al. [26],
in which the investigators tested the ability of germline genetic
variants in the CYP2D6 gene to predict tamoxifen treatment
outcomes in non-randomized postmenopausal hormone receptor-
positive patients. In their study, Schroth et al. successfully
genotyped the *3, *4, *5, *10, and *41 alleles and simultaneous-
ly analyzed gene duplication. The investigators divided the
CYP2D6 metabolizer statuses into extensive metabolizer (EM,
denoting patients with two functional alleles, including those with
ultra-rapid metabolism), heterozygote-extensive/intermediate
metabolizer (hetEM/IM, denoting patients with intermediate or
one poor metabolism allele), and poor metabolizer (PM, denoting
patients homozygous for poor metabolism alleles) based on the
genotypes of the combined *3, *4, *5, *10, and *41 alleles (Table 1
and Table 2). The decreased metabolizer (DM) was defined as the
combined PM and hetEM/IM groups. In our modeling analysis,
we classified the CYP2D6 metabolizer status into the EM group
(46%) and the DM group (hetEM+IM+PM, 54%).
Definition of survival end points. In this study, the
definitions of survival end points were in accordance with the
description in the BIG 1-98 [8] and ATAC trials [7], respectively.
Survival simulation was performed using the annual hazard rates
that were also derived from these two trials. For the BIG 1-98 trial
[8], the annual hazard rate was for ‘‘disease’’ (disease-free survival
Table 1. Model parameters definition.
Parameter Reference
Annual hazard rates for DFS (BIG 1-98) BIG 1-98 [8]
Year With an AI With tamoxifen
Year 0–1 0.0243 0.0264
Year 1–2 0.0268 0.0460
Year 2–3 0.0415 0.0469
Year 3–4 0.0414 0.0481
Year 4–5 0.0401 0.0397
Annual hazard rates for EFS (ATAC)
Year 0–1 0.0127 0.0170 ATAC [7]
Year 1–2 0.0212 0.0303
Year 2–3 0.0229 0.0291
Year 3–4 0.0212 0.0269
Year 4–5 0.0200 0.0283
Year 5–6 0.0200 0.0285
Year 6–7 0.0209 0.0264
Year 7–8 0.0217 0.0242
Year 8–9 0.0203 0.0279
Data sources for modeling Schroth et al. [26]
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recurrence in local, regional, or distant sites; a new invasive breast
cancer in the contralateral breast; any second (non-breast)
malignancy; or death from any cause. For the ATAC trial [7],
the annual hazard rate was for ‘‘event’’ (event-free survival [EFS]
as the survival end point), which was defined as a local, regional, or
distant recurrence; a new primary breast cancer (including new
contralateral tumors); or death from breast cancer-specific causes.
The hazard ratio (HR) of a ‘‘recurrence event’’ and the HR of
‘‘disease’’ for DM patients were 1.33 (95% confidence interval
[CI]: 1.06–1.68) and 1.29 (95% CI: 1.03–1.61) relative to EM
patients, respectively [26]. Unlike the model of Punglia et al. [25]
with three levels of metabolizer status, our model had only two
levels. Such a classification simplified the modeling procedure
(Table 2).
Markov model design
Markov decision models were developed using the TreeAge.Pro
2009 software (TreeAge Software, Williamstown, MA) to simulate
the clinical histories of hypothetical cohorts of postmenopausal
women with hormone receptor-positive breast cancer as previously
described [25]. The Markov model simulated the transition
between two health states, from a status of being well without any
evidence of breast cancer events (event-free or disease-free) to an
event status. The basic procedure of model establishment was as
previously described [25]. We ran the model 60 times (by monthly
cycle) to calculate the 5-year DFS probability and ran the model
108 times (by monthly cycle) to calculate the 9-year EFS
probability. Using the survival data from the BIG 1-98 trial, our
model calculated a 5-year DFS of 83.7% for those receiving an AI
(letrozole) and 80.9% for those receiving tamoxifen. These data
were consistent with the real 5-year DFS outcomes reported in the
BIG 1-98 trail (84.0% and 81.1% for letrozole and tamoxifen,
respectively). Using the data from the ATAC trial, our model
obtained a 9-year EFS of 83.2% for those receiving an AI
(anastrozole) and 78.4% for those receiving tamoxifen. These
simulated results were also similar to the real 9-year EFS outcomes
reported in the ATAC trail (83.0% and 78.2% for anastrozole and
tamoxifen, respectively).
Sensitivity analyses
We performed sensitivity analyses using the TreeAge.Pro 2009
software (TreeAge Software, Williamstown, MA). In our model,
there were two parameters: hazard ratio of DM (HR.DM) and its
frequency (f.DM). We performed the two-way sensitivity analysis by
simultaneously varying HR.DM and f.DM. HR.DM varied from 1.05
to 3.05 according to the reported 95% CI of EFS (95% CI: 1.06–
1.68 [26] and 95% CI: 1.10 to 3.25 [20]), whereas f.DM varied
according to its assumed extreme values by the following formula:
f: 4vf:DMv f: 3|2zf: 4|2zf: 5|2zf: 10|2zf: 41|2 ðÞ :
The above formula was determined according to the definition
of a DM in the original paper [26]. By reviewing the allelic
frequency data of *3/*4/*5/*10/*41 in previous reports [4,27],
we assumed the lower limit and upper limit of f.DM were
approximately 20% and 80%, respectively. Note that the real
interval of f.DM should be much narrower.
Results
The multiple-genotype-based modeling analysis
indicated a similar role of TAM to AI in postmenopausal
breast cancer women with wild-type CYP2D6 using BIG
1-98 survival data
We used the multiple-genotype-based model to examine 5-year
DFS by CYP2D6 metabolizer status. In the base case analysis, we
used an HR.DM (HR for ‘‘disease’’ among DM patients receiving
tamoxifen) of 1.29 and an f.DM of 0.54. The simulated 5-year DFS
of tamoxifen-treated EM patients was 83.3%, which was similar to
that for pharmacogenetically unselected patients treated with an
AI (letrozole) of 83.7% [8]. Figure 1A shows the DFS curves for
all patients treated with an AI or tamoxifen as well as for
tamoxifen-treated subpopulations divided by metabolizer statuses.
Notably, the simulated survival curves were derived from assumed
data rather than truly observed data. Our findings, based on the
larger sample size study [26], were consistent with the results from
another model proposed by Punglia et al. [25].
We next investigated the robustness of the findings across a
range of assumptions for HR.DM and f.DM using a two-way
sensitivity analysis by simultaneously varying HR.DM and f.DM.
The results shown in Figure 1B are from EM patients only. Each
point on this figure can be described by an (x, y) coordinate. The
x-axis plots HR.DM, whereas the y-axis plots f.DM. Each (x, y) point
represents a unique combination. The white area therefore
indicates the combinations of HR.DM and f.DM parameters, for
which tamoxifen optimizes the 5-year DFS in EM patients, and
the grey area depicts those for which an AI optimizes the 5-year
DFS in EM patients. By this analysis, we observed that when
HR.DM .1.95, almost all EM patients would benefit more from
tamoxifen than from an AI, whereas if HR.DM ,1.25, the use of
Table 2. Comparisons of two models.
Characteristics Model
Punglia’s Our
Patients number for modeling 190 1,325
Alleles in modeling *4 *3, *4, *5, *10, *41
HR of risk genotype (95%CI) HR.*4/*4=1.86 (0.91–3.82) for DFS [17] HR.DM=1.29 (1.03–1.61) for DFS
HR.DM=1.33 (1.06–1.68) for EFS [26]
Number (frequency) of PM, IM (hetEM/IM), EM(homEM) 13 (6.8%), 40 (21.1%), 137 (72.1%) 79 (5.9%), 637 (48.1%), 609 (46.0%)
#
Parameters for modeling 4 (HR.*4/*4, Eff.wt/*4, f.*4/*4, f.wt/4)2 ( HR.DM, f.DM)
DM, PM, IM, and EM denote decreased metabolizer, poor metabolizer, intermediate metabolizer, and extensive metabolizer, respectively. het. heterozygous; hom.
homozygous; DFS, disease-free survival; EFS, event-free survival; f, frequency; HR, hazard ratio.
#frequency of DM (indicating PM+IM+hetEM) is 54%.
doi:10.1371/journal.pone.0015649.t002
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HR.DM is between 1.25 and 1.95, the choice of endocrine therapy
depended on the value of f.DM. A higher f.DM represented a higher
possibility of benefiting from tamoxifen.
The comparable role of tamoxifen with AIs in women
with breast cancer who presented with wild-type CYP2D6
is successfully replicated using ATAC survival data
We further tested our model using the survival data from another
large randomized clinical trial, the ATAC [7]. In the base case
analysis, we used an HR.DM of 1.33 for EFS and an f.DM of 54%.
The 9-year EFS of tamoxifen-treated EM patients was 81.4%,
which is higher than that of genotypically unselected patients
receiving tamoxifen (78.4%) and similar to that of patients receiving
an AI (anastrozole) (83.2%). Figure 1C displays the EFS curves for
all genotypically unselected patients treated with an AI or tamoxifen
and for genotypically selected patients treated with tamoxifen.
Likewise, we performed a two-way sensitivity analysis by
varying HR.DM and f.DM (Figure 1D). Table 3 displays the
results of the sensitivity analysis in a digital form. We found that
when HR.DM .1.5, a relative higher f.DM ($60%) would warrant
the survival benefits from tamoxifen in EM patients. Once HR.DM
Figure 1. Survival simulation and two-way sensitivity analyses of the CYP2D6 multiple-genotype-based model. (A) Simulated 5-year
disease-free survival (DFS) curves for an unselected population and each metabolizer-based subgroup using the hazard rate data from the BIG 1-98
trial. We used an HR.DM of 1.29 and an f.DM of 0.54. The dotted blue line represents the AI strategy in the unselected population. The black line
represents the tamoxifen strategy in the unselected population. The tamoxifen treatment in EM patients is shown as a dotted gray line, and DM
patients are represented by the dark-gray line. The simulated 5-year DFS for EM patients, DM patients, and unselected women treated with tamoxifen
and unselected women treated with an AI were 83.3%, 77.0%, 80.9%, and 83.7%, respectively. (B) Two-way sensitivity analysis for EM patients by
varying HR.DM and f.DM using the hazard rate data from the BIG 1-98 trial. HR.DM is plotted on the x-axis, and f.DM is plotted on the y-axis. The gray area
represents the combinations of HR.DM and f.DM for which an AI optimizes the 5-year DFS for EM patients, and the white area represents those for
which tamoxifen optimizes the 5-year DFS for EM patients. (C) Simulated 9-year event-free survival (EFS) curves for an unselected population and
each metabolizer-based subgroup using the hazard rate data from the ATAC trial. We used an HR.DM of 1.33 and an f.DM of 0.54. The dotted blue line
represents the AI strategy in the unselected population. The black line represents the tamoxifen strategy in the unselected population. The tamoxifen
treatment in EM patients is shown as a dotted gray line, and DM patients are represented by the dark-gray line. The simulated 9-year EFS for EM
patients, DM patients, and unselected women treated with tamoxifen and unselected women treated with an AI were 81.4%, 76.0%, 78.4%, and
83.2%, respectively. (D) Two-way sensitivity analysis for EM patients by varying HR.DM and f.DM using the hazard rate data from the ATAC trial. The
pentalpha maker corresponds to another previously published estimate by Schroth et al. (f.DM =40%, HR.DM =1.89, 95% CI: 1.10–3.25) [20].
doi:10.1371/journal.pone.0015649.g001
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tamoxifen than from an AI. Conversely, if HR.DM ,1.3, an AI
would likely be a better option for EM patients.
Discussion
Epidemiological evidence from retrospective studies indicates an
association between CYP2D6 variations and altered tamoxifen
response in a range of therapeutic settings such as metastatic breast
cancer [28], cancer prevention [29], and adjuvant therapy
[17,18,20,21]. In the adjuvant setting, some studies have suggested
that PM/IM patients might gain insufficient therapeutic benefits
from tamoxifen and be at a higher risk of breast cancer relapse
than EM patients. The present study is based on the assumption
that the pharmacogenetics of tamoxifen biotransformation is
associated with clinical outcomes. We constructed a CYP2D6
multiple-genotype-based model using two convenient parameters,
the HR of DM (HR.DM) and its frequency (f.DM). Our model is
more feasible to perform and is likely more reliable than a single
allele (*4)-based model. We also replicated the modeling outcome
with survival data from another large trial, the ATAC trial. The
validation results were consistent with the initial findings.
The current study strongly suggests that the adjuvant endocrine
therapy should be tailored for an individual patient according to
her multiple CYP2D6 genotypes. This statement, however, may be
premature. Only one side of the coin is being considered by
looking at CYP2D6 genotypes for tamoxifen metabolism, and there
are many other factors involved in endocrine therapy response.
For example, CYP19 genotypes might modulate AI metabolism
[30]; the alleles of ABCC2 have been shown to have an additive
effect on recurrence-free survival outcome of adjuvant tamoxifen
therapy for breast cancer patients. Furthermore, the role of tumor
characteristics was not considered in the present study. In one
report, a composite index comprising of host CYP2D6 polymor-
phisms along with tumor homeobox-13 and interleukin-17B
receptor ratio could accurately predict tamoxifen sensitivity than
either alone [31]. To date, no prospective trial has been conducted
to test the hypothesis that CYP2D6 pharmacogenetic testing can
predict tamoxifen response. The available evidence does support
the launch of a clinical trial to scrutinize the value of CYP2D6
genotypes in endocrine therapy selection. In fact, AIs are not
always appropriate for ‘‘all’’ postmenopausal patients in clinic
practice due to their common toxicity resulting in arthralgias and/
or bone pain as well as their higher cost [12]. Despite the absence
of primary evidence from prospective trials, it seems reasonable at
present the use clinical judgment to utilize CYP2D6 testing under
certain conditions; however, its use should be confined [32].
Our modeling analyses have unavoidable limitations. First, in
addition to CYP2D6, other CYP isoforms such as CYP3A4/5,
CYP2C19, CYP2C9, and CYP2B6 appear to play less important
but somewhat unique roles in tamoxifen metabolism [3]. The
present multiple-genotype-based model still fails to integrate them
together because of insufficient resource data. Second, our model is
only applicable to Caucasian women, as the distribution and
frequency of CYP2D6 genotypes in Asians and Africans are
somewhat different [16]. Third, tamoxifen metabolism can be
mediated by pharmacologic inhibitors of CYP2D6 [3,33]. Certain
selective serotonin reuptake inhibitors (SSRIs) are potent inhibitors
of CYP2D6, and co-administration of SSRIs would negatively alter
the efficacy of tamoxifen [3,33]. Our model did not consider the
effect of comedication of CYP2D6 inhibitors on survival outcomes.
Taken together, the current evidence is still not strong enough
to warrant an ethical obligation for physicians to inform
postmenopausal patients with hormone receptor-positive breast
cancer about the CYP2D6 genotype testing when deciding between
tamoxifen and an AI in an adjuvant setting. The findings in the
present study, however, strongly suggest that adjuvant endocrine
therapy should be tailored to each individual patient according to
her genetic information, especially for those women who are
concerned about the toxicity or cost of AIs.
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